OPEN END TURBO OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 01:12:11 22/06/2024 am IST | ||
| 14.95 EUR | -0.27% |
|
| Current month | +9.68% | ||
| 1 month | +18.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 14.95 | -0.27% |
| 20/24/20 | 14.99 | +2.74% |
| 19/24/19 | 14.59 | -0.68% |
| 18/24/18 | 14.69 | -3.86% |
| 17/24/17 | 15.28 | -4.74% |
Delayed Quote Börse Stuttgart
Last update June 22, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB4FZG |
| ISIN | DE000JB4FZG2 |
| Date issued | 16/10/2023 |
| Strike | 311.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.36 € |
|---|---|
| Lowest since issue | 4.69 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Certificates
- Certificat
